Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2025)

Zevra Therapeutics' Gross Profit history spans 6 years, with the latest figure at $32.6 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 206.0% year-over-year to $32.6 million; the TTM value through Dec 2025 reached $90.1 million, up 457.46%, while the annual FY2025 figure was $90.0 million, 456.25% up from the prior year.
  • Gross Profit reached $32.6 million in Q4 2025 per ZVRA's latest filing, up from $24.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $32.6 million in Q4 2025 to a low of $32000.0 in Q3 2022.
  • Average Gross Profit over 5 years is $8.5 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Gross Profit: tumbled 98.37% in 2022, then surged 8496.88% in 2023.
  • A 5-year view of Gross Profit shows it stood at $2.5 million in 2021, then skyrocketed by 289.93% to $9.8 million in 2022, then increased by 18.86% to $11.7 million in 2023, then dropped by 8.79% to $10.7 million in 2024, then soared by 206.0% to $32.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Gross Profit are $32.6 million (Q4 2025), $24.9 million (Q3 2025), and $13.5 million (Q2 2025).